SCHEMBL1839628

SCHEMBL1839628

O=C(O)C1CCN(C(=O)c2ccco2)CC1

nearest known ligand 0.76

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.76
PKM P14618 1/20 0.76
LMNA P02545 2/20 0.68
NPC1 O15118 1/20 0.65
PTPN2 P17706 1/20 0.64
PTPN1 P18031 1/20 0.64
RAB9A P51151 1/20 0.62
KDM4E B2RXH2 2/20 0.61
ALDH1A1 P00352 7/20 0.61
KMT2A Q03164 2/20 0.61
NPSR1 Q6W5P4 2/20 0.60
HTT P42858 1/20 0.60
MAPK1 P28482 1/20 0.59
TDP1 Q9NUW8 1/20 0.58
TSHR P16473 2/20 0.57
CXCR4 P61073 1/20 0.56
TP53 P04637 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6209326 0.85 KMT2A (0.73) SMN1; SMN2PKMLMNANPC1PTPN2
SCHEMBL16026437 0.83 ALDH1A1 (0.83) SMN1; SMN2PKMLMNANPC1RAB9A
SCHEMBL12593269 0.83 SMN1; SMN2 (0.68) SMN1; SMN2PKMLMNANPC1PTPN2
SCHEMBL27080814 0.83 SMN1; SMN2 (0.73) SMN1; SMN2PKMLMNANPC1PTPN2
SCHEMBL2636628 0.82 ALDH1A1 (0.70) SMN1; SMN2PKMLMNANPC1RAB9A
SCHEMBL27508890 0.82 RAB9A (0.84) SMN1; SMN2PKMLMNANPC1RAB9A
SCHEMBL7238822 0.81 ALDH1A1 (0.64) SMN1; SMN2PKMLMNARAB9AKDM4E
SCHEMBL3099181 0.80 ALDH1A1 (0.73) SMN1; SMN2LMNANPC1RAB9AKDM4E
SCHEMBL4431424 0.80 SMN1; SMN2 (0.65) SMN1; SMN2PKMLMNANPC1PTPN2
SCHEMBL61103 0.78 ALDH1A1 (0.87) SMN1; SMN2PKMLMNANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8957205-B2 Cycloalkane carboxamide derivatives and production process of same SEIKAGAKU CORPORATION (JP) 2015-02-17 US disclosed
US-8829209-B2 Cycloalkylcarbonylamino acid ester derivative and process for producing the same SEIKAGAKU CORPORATION (JP) 2014-09-09 US disclosed
US-8785631-B2 Oxazolone derivative compounds having a 3-oxa-1-azaspiro[4.5] core SEIKAGAKU CORPORATION (JP) 2014-07-22 US disclosed
CN-101370773-B Cycloalkanecarboxamide derivative and method for producing same SEIKAGAKU KOGYO CO LTD 2014-04-09 CN disclosed
US-8481725-B2 Cycloalkylcarbonylamino acid derivative and process for producing the same SEIKAGAKU CORPORATION (JP) 2013-07-09 US disclosed
EP-1975162-B1 OXAZOLONE DERIVATIVE SEIKAGAKU KOGYO CO LTD (JP) 2012-08-15 EP disclosed
EP-1972636-B1 CYCLOALKYLCARBONYLAMINO ACID DERIVATIVE AND PROCESS FOR PRODUCING THE SAME SEIKAGAKU KOGYO CO LTD (JP) 2011-05-25 EP disclosed
EP-2036920-B1 CYCLOALKYLCARBONYLAMINO ACID ESTER DERIVATIVE AND PROCESS FOR PRODUCING THE SAME SEIKAGAKU KOGYO CO LTD (JP) 2011-05-18 EP disclosed
US-20090156805-A1 Cycloalkane Carboxamide Derivatives and Production Process of Same SEIKAGAKU CORPORATION (JP) 2009-06-18 US disclosed
US-20090137799-A1 Cycloalkylcarbonylamino Acid Ester Derivative and Process for Producing The Same SEIKAGAKU CORPORATION (JP) 2009-05-28 US disclosed
US-20090131661-A1 Oxazolone Derivatives SEIKAGAKU CORPORATION (JP) 2009-05-21 US disclosed
US-20090111983-A1 Cycloalkylcarbonylamino Acid Derivative and Process For Producing The Same SEIKAGAKU CORPORATION (JP) 2009-04-30 US disclosed
EP-2036920-A1 CYCLOALKYLCARBONYLAMINO ACID ESTER DERIVATIVE AND PROCESS FOR PRODUCING THE SAME SEIKAGAKU CORPORATION (JP) 2009-03-18 EP disclosed
CN-101370773-A Cycloalkanecarboxamide derivative and method for producing same SEIKAGAKU KOGYO CO LTD (JP) 2009-02-18 CN disclosed
EP-1975162-A1 OXAZOLONE DERIVATIVE SEIKAGAKU CORPORATION (JP) 2008-10-01 EP disclosed
EP-1972636-A1 CYCLOALKYLCARBONYLAMINO ACID DERIVATIVE AND PROCESS FOR PRODUCING THE SAME SEIKAGAKU CORPORATION (JP) 2008-09-24 EP disclosed
EP-1972615-A1 CYCLOALKANECARBOXAMIDE DERIVATIVE AND METHOD FOR PRODUCING SAME SEIKAGAKU CORPORATION (JP) 2008-09-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131661-A1 Oxazolone Derivatives CTSK, CTSZ, CTSV SMN1; SMN2 3923/4885PKM 1173/4885LMNA 1018/4885
US-20090156805-A1 Cycloalkane Carboxamide Derivatives and Production Process of Same CTSK, CTSS, CTSB SMN1; SMN2 4556/4885PKM 765/4885LMNA 3170/4885
US-20090137799-A1 Cycloalkylcarbonylamino Acid Ester Derivative and Process for Producing The Same CTSK, CTSS, CTSE SMN1; SMN2 4555/4885PKM 880/4885LMNA 2238/4885
US-20090111983-A1 Cycloalkylcarbonylamino Acid Derivative and Process For Producing The Same CTSK, CTSS, CTSV SMN1; SMN2 4647/4885PKM 780/4885LMNA 1792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.